| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04c0e2a5d994f559e9dc5c6eeb1fd5b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75d91771310e1b59c0fd8b5a7e1d8122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_053735b8814b279c20f299a0f4a4266e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f363713ae73bc024e107e70e6865c6e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-40 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-50 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475 |
| filingDate |
2015-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_596bf1eec1bb5b1daee02521820a1da4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99188363e72040deea72c1ffe251669c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26ce7112fdb65b0d5f902f0c727e4d3a |
| publicationDate |
2020-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10736948-B2 |
| titleOfInvention |
Epidermal growth factor fusion proteins with mutant cholera toxin B subunits |
| abstract |
The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host. |
| priorityDate |
2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |